Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
- 1 January 2007
- journal article
- research article
- Published by CSIRO Publishing in Sexual Health
- Vol. 4 (3) , 147-163
- https://doi.org/10.1071/sh07042
Abstract
Vaccines are now available to prevent the development of cervical cancer from genital human papillomavirus (HPV) infection. The decision to vaccinate depends on a vaccine's cost-effectiveness. A rigorous cost-effectiveness model for vaccinated individuals is presented in a companion paper; this paper investigates the additional benefits the community might receive from herd immunity.Keywords
This publication has 35 references indexed in Scilit:
- Vaccines for cervical cancerEpidemiology and Infection, 2006
- Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial NeoplasiaObstetrics & Gynecology, 2006
- The epidemiology of genital human papillomavirus infectionVaccine, 2005
- Human papillomavirus infection: biology, epidemiology, and preventionInternational Journal of Gynecologic Cancer, 2005
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialThe Lancet Oncology, 2005
- The papillomavirus life cycleJournal of Clinical Virology, 2005
- The epidemiology of human papillomavirus infectionsPublished by Elsevier ,2005
- Human Papillomavirus and Cervical CancerClinical Microbiology Reviews, 2003
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002
- Epidemiology of genital human papillomavirus infectionsBulletin de l'Institut Pasteur, 1997